The Global Health Body Sounds Warning Over Critical Scarcity of Obesity Jabs

Under a tenth of people that would benefit from obesity jabs like Wegovy are able to get them, caution the global health agency as it releases its inaugural recommendations on the therapies.

Given over a billion individuals worldwide now classified as obese, it is calling for more widespread and fairer access to this class of drugs.

Per projections, in excess of 2,000,000,000 are projected to be obese by 2030 if no action is taken.

"Our new guidance affirms that obesity is a lifelong illness that can be treated with holistic and lifelong support," said the agency's head Tedros Adhanom Ghebreyesus.

High costs, insufficient output, and distribution challenges are major obstacles to universal access to the jabs that can aid individuals in losing significant body mass, says the agency.

Weight-Loss Drug Supply Crisis

Even under the present most favorable case, the production of these medications could only cover approximately 100 million people – less than 10% of those who need them, per the health organization.

The advice calls on countries and companies to increase access, via strategies including licensing agreements.

Exclusive production rights on semaglutide – the main ingredient of the drug Wegovy – is set to lapse in a number of countries in 2026.

How Obesity Injections Work

The injections imitate a body's own hormone to delay gastric emptying, curb appetite and enhance feelings of fullness so people reduce food intake.

People usually start to lose weight within a few weeks of beginning the once-weekly jabs.

Studies indicates users may regain a significant portion after a year of halting the drug, as their usual hunger return.

Being overweight or obese increases your likelihood for contracting diseases, such as type 2 diabetes, cardiovascular issues, stroke, and some malignancies.

Excess weight impacts people in all nations and was associated with 3.7 million fatalities worldwide in 2024, per the health agency.